- Home
- USCB vs CDXS Comparison
USCB vs CDXS Comparison
Compare USCB & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- CDXS
- Stock Information
- Founded
- USCB 2002
- CDXS 2002
- Country
- USCB United States
- CDXS United States
- Employees
- USCB N/A
- CDXS N/A
- Industry
- USCB Major Banks
- CDXS Major Chemicals
- Sector
- USCB Finance
- CDXS Industrials
- Exchange
- USCB Nasdaq
- CDXS Nasdaq
- Market Cap
- USCB 316.4M
- CDXS 254.3M
- IPO Year
- USCB 2021
- CDXS 2010
- Fundamental
- Price
- USCB $18.51
- CDXS $3.04
- Analyst Decision
- USCB Buy
- CDXS Buy
- Analyst Count
- USCB 3
- CDXS 2
- Target Price
- USCB $20.33
- CDXS $11.00
- AVG Volume (30 Days)
- USCB 27.5K
- CDXS 832.6K
- Earning Date
- USCB 07-24-2025
- CDXS 08-07-2025
- Dividend Yield
- USCB 2.15%
- CDXS N/A
- EPS Growth
- USCB 69.00
- CDXS N/A
- EPS
- USCB 1.47
- CDXS N/A
- Revenue
- USCB $88,094,000.00
- CDXS $49,815,000.00
- Revenue This Year
- USCB $23.28
- CDXS $12.53
- Revenue Next Year
- USCB $7.02
- CDXS $22.54
- P/E Ratio
- USCB $12.65
- CDXS N/A
- Revenue Growth
- USCB 32.06
- CDXS N/A
- 52 Week Low
- USCB $13.84
- CDXS $1.90
- 52 Week High
- USCB $21.86
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- USCB 67.32
- CDXS 57.14
- Support Level
- USCB $17.12
- CDXS $2.77
- Resistance Level
- USCB $18.45
- CDXS $3.39
- Average True Range (ATR)
- USCB 0.49
- CDXS 0.20
- MACD
- USCB 0.09
- CDXS 0.01
- Stochastic Oscillator
- USCB 89.62
- CDXS 50.70
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.